Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis A virus infection in vitro and in vivo.
Hepatitis A virus (HAV) is the major pathogen responsible for acute infectious hepatitis A, a disease that is prevalent worldwide. Although HAV immunization effectively prevents infection, primary immunizations must be administered at least 2 weeks prior to HAV exposure. In contrast, passive immunization with pooled human immunoglobulin (Ig) can provide immediate and rapid protection from HAV infection. Because the use of human sera-derived Igs carries the risk of contamination, we sought to develop recombinant HAV-neutralizing human antibodies. We prepared a combinatorial phage display library of recombinant human anti-HAV antibodies from RNA extracted from the blood lymphocytes of a convalescent hepatitis A patient. Two recombinant human IgG antibodies, HAIgG16 and HAIgG78, were screened from the antibody library by their ability to bind with high affinity to purified, inactivated HAV virions. These antibodies recognized different epitopes of the HAV virion capsid, and competed with both patient sera and well-characterized neutralizing mouse monoclonal antibodies. A cocktailed mixture of HAIgG16 and HAIgG78 at a 3:1 ratio was prepared to compare its combined biological activity with that conferred by each antibody individually. The cocktailed antibodies displayed a stronger neutralizing activity in vitro than that observed with either HAIgG16 and HAIgG78 alone. To determine the in vivo neutralizing abilities of these antibodies, rhesus monkeys were inoculated with cocktailed antibodies and challenged with HAV. Whereas control animals developed hepatitis A and seroconverted to the HAV antibody, animals receiving cocktailed antibodies were protected either from viral infection or from developing clinical hepatitis. These results demonstrate that recombinant human antibody preparations could be used to prevent or treat early-stage HAV infection.
Cao
Jingyuan
J
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, China CDC, Xuan Wu Qu, Beijing, China.
Meng
Shufang
S
Li
Chuan
C
Ji
Yan
Y
Meng
Qingling
Q
Zhang
Quanfu
Q
Liu
Feng
F
Li
Jiandong
J
Bi
Shengli
S
Li
Dexin
D
Liang
Mifang
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000915:Antibody Affinity; D002460:Cell Line; D018604:Epitope Mapping; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D035922:Hepatitis A Antibodies / Q000276:immunology* / Q000627:therapeutic use; D035921:Hepatitis A Antigens / Q000276:immunology; D030041:Hepatitis A virus / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D008099:Liver / Q000473:pathology / Q000821:virology; D008253:Macaca mulatta; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D035922:Hepatitis A Antibodies; D035921:Hepatitis A Antigens; D011994:Recombinant Proteins